Sanofi Pre-Tax Profit Margin 2010-2024 | SNY
Current and historical pre-tax profit margin for Sanofi (SNY) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Sanofi pre-tax profit margin for the three months ending September 30, 2024 was .
| Sanofi Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$53.03B |
$6.67B |
12.58% |
| 2024-06-30 |
$51.29B |
$6.12B |
11.94% |
| 2024-03-31 |
$50.68B |
$6.57B |
12.96% |
| 2023-12-31 |
$50.27B |
$7.74B |
15.40% |
| 2023-09-30 |
$49.01B |
$12.13B |
24.75% |
| 2023-06-30 |
$48.42B |
$11.52B |
23.78% |
| 2023-03-31 |
$48.20B |
$11.01B |
22.85% |
| 2022-12-31 |
$47.82B |
$10.98B |
22.96% |
| 2022-09-30 |
$48.72B |
$10.22B |
20.98% |
| 2022-03-31 |
$34.76B |
$8.47B |
24.36% |
| 2021-09-30 |
$35.03B |
$8.73B |
24.91% |
| 2021-03-31 |
$43.57B |
$9.70B |
22.25% |
| 2020-09-30 |
$42.75B |
$8.86B |
20.71% |
| 2020-03-31 |
$41.19B |
$7.47B |
18.14% |
| 2019-09-30 |
$41.49B |
$6.12B |
14.76% |
| 2019-03-31 |
$41.50B |
$6.08B |
14.64% |
| 2018-03-31 |
$41.43B |
$5.98B |
14.44% |
| 2017-12-31 |
$40.92B |
$6.25B |
15.28% |
| 2017-09-30 |
$40.25B |
$6.63B |
16.48% |
| 2017-06-30 |
$39.59B |
$6.79B |
17.16% |
| 2017-03-31 |
$39.14B |
$6.89B |
17.59% |
| 2016-12-31 |
$38.41B |
$6.28B |
16.36% |
| 2016-09-30 |
$39.27B |
$7.14B |
18.17% |
| 2016-06-30 |
$39.37B |
$6.82B |
17.33% |
| 2016-03-31 |
$41.16B |
$6.87B |
16.68% |
| 2015-09-30 |
$42.97B |
$6.43B |
14.95% |
| 2015-06-30 |
$43.92B |
$6.27B |
14.27% |
| 2014-06-30 |
$44.70B |
$6.92B |
15.49% |
| 2013-06-30 |
$45.22B |
$6.43B |
14.23% |
| 2012-06-30 |
$46.75B |
$8.86B |
18.96% |
| 2012-03-31 |
$47.10B |
$8.39B |
17.82% |
| 2011-12-31 |
$47.27B |
$7.41B |
15.67% |
| 2011-09-30 |
$45.65B |
$6.56B |
14.36% |
| 2011-06-30 |
$44.35B |
$5.47B |
12.33% |
| 2011-03-31 |
$42.93B |
$6.49B |
15.12% |
| 2010-12-31 |
$41.26B |
$7.44B |
18.02% |
| 2010-09-30 |
$41.28B |
$9.46B |
22.92% |
| 2010-06-30 |
$41.42B |
$9.82B |
23.72% |
| 2010-03-31 |
$41.35B |
$8.98B |
21.72% |
| 2009-12-31 |
$40.79B |
$8.46B |
20.74% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$135.190B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
